The Infantile Spasm (West Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Infantile Spasm (West Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Infantile Spasm (West Syndrome) by eight companies/universities/institutes. The top development phase for Infantile Spasm (West Syndrome) is preclinical with four drugs in that stage. The Infantile Spasm (West Syndrome) pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Infantile Spasm (West Syndrome) pipeline products market are: Bio-Pharm Solutions, Cerecin and Anavex Life Sciences.
The key targets in the Infantile Spasm (West Syndrome) pipeline products market include Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1), Sigma Non Opioid Intracellular Receptor 1 (Aging Associated Gene 8 Protein or SR31747 Binding Protein or Sigma 1 Type Opioid Receptor or SIGMAR1), and Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4).
The key mechanisms of action in the Infantile Spasm (West Syndrome) pipeline product include Melanocortin Receptor Agonist with one drug in Unknown. The Infantile Spasm (West Syndrome) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Infantile Spasm (West Syndrome) pipeline products market including Small Molecule, and Peptide.
Infantile Spasm (West Syndrome) overview
Infantile Spasm also known as West Syndrome is a type of seizures and most seen in children. Observed in children up to 5 years of age and can develop into other seizures in rare cases. Sudden stiffening of arms and legs, head thrown back, commonly observed when woke up from sleep and rare in sleep. These seizures last for four to five seconds. It is a rare form of seizure that stops by the age four or five. Trauma, genetic causes, metabolic causes, are common etiological factors. Physical examination, CT scan, EEG findings, MRI are by which diagnosis done. Hormonal therapy with prednisolone, anti-seizure medications with ketogenic diet is recommended.
For a complete picture of Infantile Spasm (West Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
